×
Avadel Pharmaceuticals Price/Book Ratio 2010-2024 | AVDL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Avadel Pharmaceuticals price/book ratio from 2010 to 2024. Price/book ratio can be defined as
View More
Avadel Pharmaceuticals Price/Book Ratio 2010-2024 | AVDL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Avadel Pharmaceuticals price/book ratio from 2010 to 2024. Price/book ratio can be defined as
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.2B
Takeda Pharmaceutical (TAK)
$43.3B
Sandoz Group AG (SDZNY)
$19.5B
Merck (MKKGY)
$19.2B
Astellas Pharma (ALPMY)
$18.2B
United Therapeutics (UTHR)
$16.1B
Summit Therapeutics (SMMT)
$14.7B
Neurocrine Biosciences (NBIX)
$12.1B
Shionogi (SGIOY)
$11.9B
Catalent (CTLT)
$10.7B
Jazz Pharmaceuticals (JAZZ)
$7.1B
Madrigal Pharmaceuticals (MDGL)
$6.9B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$5.7B
Ionis Pharmaceuticals (IONS)
$5.3B
Crinetics Pharmaceuticals (CRNX)
$5.1B
PTC Therapeutics (PTCT)
$3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Arrowhead Pharmaceuticals (ARWR)
$2.3B
Soleno Therapeutics (SLNO)
$2.2B
NewAmsterdam Pharma (NAMS)
$2.2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Evotec AG (EVO)
$1.8B
Recursion Pharmaceuticals (RXRX)
$1.8B
Xencor (XNCR)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Indivior (INDV)
$1.4B
Harrow (HROW)
$1.4B